Table 4e. Characteristics of Antiviral Agents, Including Antibody Products
Last Updated: December 1, 2022
- This table contains drugs and products that have shown antiviral activity against SARS-CoV-2, including small-molecule antiviral drugs, mAbs, CCP, and IFNs.
- RDV is the only antiviral drug that is approved by the FDA for the treatment of COVID-19.
- RTV-boosted nirmatrelvir, MOV, and CCP have received EUAs from the FDA for the treatment of COVID-19. TIX plus CIL received an EUA for SARS-CoV-2 PrEP.
- Other medications that are currently being evaluated in clinical trials for the treatment of COVID-19 are also included in this table. The inclusion of these drugs does not imply that the Panel recommends their use.
- For drug-drug interaction information, please refer to product labels, EUA fact sheets, and Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications.
- For the Panel’s recommendations on using the drugs listed in this table, please refer to the individual drug sections, Therapeutic Management of Nonhospitalized Adults With COVID-19, Therapeutic Management of Hospitalized Adults With COVID-19, Therapeutic Management of Nonhospitalized Children With COVID-19, or Antiviral Agents, Including Antibody Products.
Table 4e. Characteristics of Antiviral Agents, Including Antibody Products | |
|---|---|
References
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. 2022. Available at: https://www.fda.gov/media/155050/download.
- (CTC) BCTC, COVID Therapy Review and Advisory Working Group (CTRAWG). Therapeutic brief: crushing nirmatrelvir/ritonavir (Paxlovid). 2022. Available at: http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-treatment/Crushing_Paxlovid.pdf.
- Remdesivir (Veklury) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214787Orig1s015lbl.pdf.
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules. 2022. Available at: https://www.fda.gov/media/155054/download.
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab). 2022. Available at: https://www.fda.gov/media/154701/download.
- Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016;14(2):152-157. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26674811.